Skip to main content
. 2017 Mar 10;7(4):e00648. doi: 10.1002/brb3.648

Figure 2.

Figure 2

Serum CXCL13 levels. (a) Serum CXCL13 levels of neuromyelitis optica (NMO), multiple sclerosis (MS), and control group (mean ± SE). (b) Serum CXCL13 levels in patients with NMO treated with immunosuppressive agents (group A, = 16), patients with NMO untreated with immunosuppressive agents (group B, = 8), and controls (control group) (mean ± SE). (c, d) Correlation between CXCL13 and duration to the last relapse or the onset age